Published in Blood on June 01, 1982
Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care (2013) 3.65
Management of bleeding following major trauma: an updated European guideline. Crit Care (2010) 3.09
Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol (1987) 1.53
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care (2016) 1.43
Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest (2000) 1.41
von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest (1986) 1.28
Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest (1987) 1.27
Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC). J Clin Invest (1982) 1.23
Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation. Proc Natl Acad Sci U S A (1985) 1.23
In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease. Proc Natl Acad Sci U S A (1985) 1.08
Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences. J Clin Invest (1991) 1.03
Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo. J Clin Invest (1985) 1.03
Analysis of the complexity of the multimeric structure of factor VIII related antigen/von Willebrand protein using a modified electrophoretic technique. J Clin Pathol (1983) 1.03
Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) (1985) 1.03
Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors. J Clin Invest (1987) 1.01
Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis (2014) 1.00
Role of von Willebrand factor in the haemostasis. Blood Transfus (2011) 0.87
Expression of abnormal von Willebrand factor by endothelial cells from a patient with type IIA von Willebrand disease. Proc Natl Acad Sci U S A (1987) 0.83
Clinical measurement of von Willebrand factor by fluorescence correlation spectroscopy. Clin Chem (2012) 0.82
Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura. Pediatr Nephrol (2008) 0.79
Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate. J Clin Pathol (1988) 0.79
Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) (1986) 0.75
Integrated fluorescence correlation spectroscopy device for point-of-care clinical applications. Biomed Opt Express (2013) 0.75
Failure of sodium pentobarbital anesthesia to alter 1-desamino-8-D-arginine vasopressin-induced elevations of plasma factor VIII/ von Willebrand factor in normal dogs. Can J Vet Res (1988) 0.75
Point of care and factor concentrate-based coagulation algorithms. Transfus Med Hemother (2015) 0.75
Comparison of two dimensional immunoelectrophoresis and multimer analysis in the study of von Willebrand factor. J Clin Pathol (1988) 0.75
Heat treatment in von Willebrand's disease. Br Med J (Clin Res Ed) (1985) 0.75
Outbreak of hepatitis A among Italian patients with haemophilia. Lancet (1992) 5.64
Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell (1996) 5.12
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell (1998) 4.18
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 3.56
Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet (1985) 3.53
Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A (2001) 3.07
Platelets have more than one binding site for von Willebrand factor. J Clin Invest (1983) 2.89
Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest (1980) 2.88
Eliminating parvovirus B19 from blood products. Lancet (1994) 2.85
The complex multimeric composition of factor VIII/von Willebrand factor. Blood (1981) 2.76
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
Effects of exposure to air pollution on blood coagulation. J Thromb Haemost (2006) 2.52
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost (2005) 2.45
Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol (1996) 2.38
High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med (1998) 2.30
Affinity modulation of the alpha IIb beta 3 integrin (platelet GPIIb-IIIa) is an intrinsic property of the receptor. Cell Regul (1990) 2.29
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol (1988) 2.28
Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A (1990) 2.23
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest (1977) 2.07
End4p/Sla2p interacts with actin-associated proteins for endocytosis in Saccharomyces cerevisiae. Mol Biol Cell (1997) 2.07
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood (2000) 2.05
Blood coagulation initiation by a complement-mediated pathway. J Exp Med (1971) 2.04
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
Sphingoid base signaling via Pkh kinases is required for endocytosis in yeast. EMBO J (2001) 2.02
Glanzmann thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci U S A (1982) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. J Exp Med (1971) 1.97
Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A (2000) 1.94
Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell (1989) 1.92
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
von Willebrand factor and von Willebrand disease. Blood (1987) 1.83
Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost (1996) 1.83
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost (2008) 1.81
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
Amino acid sequence of the von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Proc Natl Acad Sci U S A (1987) 1.73
von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem (1986) 1.71
Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem (1992) 1.70
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost (2006) 1.70
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Genetic screening for hemophilia A (classic hemophilia) with a polymorphic DNA probe. N Engl J Med (1985) 1.67
Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest (1978) 1.66
Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem (1987) 1.63
The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem (1986) 1.62
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost (2010) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Effect on blood coagulation of massive intravascular haemolysis. Blood (1969) 1.61
Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (factor 8(). J Clin Invest (1971) 1.61
Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost (2012) 1.57
A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost (2001) 1.57
Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem (1996) 1.57
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
Determination of the von Willebrand's disease antigen (factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis. J Lab Clin Med (1975) 1.54
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost (2003) 1.53
Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood (1984) 1.52
Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell (1985) 1.51
Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood (1998) 1.51
Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation (2000) 1.48
Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost (2006) 1.48
Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion (1995) 1.48
Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. J Biol Chem (1991) 1.48
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood (1998) 1.47
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med (2010) 1.47
Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol (1975) 1.47
Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. Neurology (2003) 1.46
Enhanced botrocetin-induced type IIB von Willebrand factor binding to platelet glycoprotein Ib initiates hyperagglutination of normal platelets. Am J Hematol (1990) 1.46
Rare coagulation disorders. Thromb Haemost (1999) 1.46
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
Morphometry of dermal nerve fibers in human skin. Neurology (2011) 1.45
von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease. J Clin Invest (1978) 1.45
Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med (1997) 1.45
Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest (1985) 1.44